Novo Nordisk upgrades guidance after sales increase
The pharmaceutical firm’s sales increase was driven by Ozempic and other GLP-1 diabetes treatments. (Updated)
by chrisopher due karlsson, translated by catherine brett & daniel pedersen
Novo Nordisk’s operating profit has increased by 28% in Danish kroner and by 14% at constant exchange rates (CER) to DKK 57.7bn (USD 7.6bn) for the first nine months of the year, the firm reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Swedish bank raises expectations for Novo Nordisk
For subscribers
Eli Lilly eyes unprecedented demand for Mounjaro
For subscribers
